Last reviewed · How we verify
NCT07035041: D2570-202
A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis
Phase 2 trial testing D-2570 in UC - Ulcerative Colitis in 120 participants. Currently enrolling.
30 July 2026
Quick facts
| Lead sponsor | InventisBio Co., Ltd |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 120 |
| Start date | 22 May 2025 |
| Primary completion | 30 July 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- D-2570 — full drug profile →
- Placebo
Conditions studied
- UC - Ulcerative Colitis — all drugs for UC - Ulcerative Colitis →
- Moderately to Severely Active Ulcerative Colitis — all drugs for Moderately to Severely Active Ulcerative Colitis →
Sponsor
InventisBio Co., Ltd — full company profile →
Who can join
Adults 18 to 70, any sex, with UC - Ulcerative Colitis or Moderately to Severely Active Ulcerative Colitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Advancing therapeutic frontiers: a pipeline of novel drugs for UC management.
Bertin L, Massano A, Redavid C, Scarpa M, et al · · 2026 · PMID 41822012 · DOI 10.3389/fgstr.2026.1747118
Verify or expand the search:
- PubMed search for NCT07035041
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of D-2570
Trials testing the same drug.
- NCT07311200 — A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) · Phase 2 · not yet recruiting
- NCT07315061 — A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis · Phase 2 · recruiting
- NCT07130604 — Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 3 · recruiting
- NCT07275775 — Single and Multiple Dose and Food Effect Study to Evaluate the Safety, Tolerability and Pharmacokinetics of D-2570 Table · Phase 1 · completed
- NCT06278350 — Evaluate the Efficacy and Safety of D-2570 in Participants With Moderate-to-Severe Plaque Psoriasis · Phase 2 · completed
Other recruiting trials for UC - Ulcerative Colitis
Currently open trials in the same condition.
- NCT07385131 — Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD · recruiting
Other InventisBio Co., Ltd trials
Trials by the same sponsor.
- NCT07411742 — Mass Balance Study of [14C] D-2570 · Phase 1 · not yet recruiting
- NCT07311200 — A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE) · Phase 2 · not yet recruiting
- NCT07326813 — A Clinical Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of Moderate to Severe Plaque Psoriasis. · Phase 3 · not yet recruiting
- NCT07315061 — A Phase II Study to Evaluate the Efficacy and Safety of D-2570 in Subjects With Active Psoriatic Arthritis · Phase 2 · recruiting
- NCT07130604 — Evaluate the Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaque Psoriasis · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07035041 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by InventisBio Co., Ltd
- Last refreshed: 24 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07035041.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing